Immune checkpoint inhibitor-induced musculoskeletal manifestations
Rheumatology International · 2021-01 · 41 (1) · 33-42
DOI: 10.1007/s00296-020-04665-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology International, online erschienen am 02.08.2020. Verfasst von Foteini Angelopoulou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab and durvalumab. We identified 3 prospective studies, 17 retrospective studies and 4 case series reporting 363 patients in total. Combined data from all three prospective studies provide a prevalence rate of 6.13%. Most patients were males (59.68%) and the vast majority (73%) were on programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. Most studies report a median time of ≤ 12 weeks from first ICI administration to symptom onset. The main clinical phenotypes reported were: (a) inflammatory arthritis (57.57%), (b) myositis (14.04%) and (c) polymyalgia rheumatica (PMR) (12.12%). A total of 256 patients required steroids (70.52%) and 67 patients (18.45%) were treated with DMARDs. Positive auto-antibodies and family history of any autoimmune disease were present in 18.48% and 19.04% of cases, respectively. Only a few patients (19%) had to discontinue treatment due to musculoskeletal Ir-AE. Two prospective studies show that significantly more patients with musculoskeletal Ir-AE exhibit a favorable oncologic response compared to patients not exhibiting such manifestations whereas retrospective studies show that 77.22% of patients with musculoskeletal Ir-AE have a good tumor response. One out of 15 patients treated with ICI will develop musculoskeletal Ir-AE; in most cases the severity of these manifestations is mild/moderate and usually ICI may be continued. Rheumatologists should familiarize with this new clinical entity and develop relevant therapeutic algorithms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece.
- Department of Rheumatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41 110, Larissa, Greece.
- 4th Department of Internal Medicine Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece. jimdaoussis@hotmail.com.
ORCID-Profile: Foteini Angelopoulou, Dimitrios Bogdanos, Theodoros Dimitroulas, Lazaros Sakkas, Dimitrios Daoussis
Zitieren
APA
Angelopoulou, F., Bogdanos, D., Dimitroulas, T., Sakkas, L., & Daoussis, D. (2021). Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatology International, 41(1), 33-42. https://doi.org/10.1007/s00296-020-04665-7
Vancouver
Angelopoulou F, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatology International. 2021;41(1):33-42. doi:10.1007/s00296-020-04665-7
BibTeX
@article{Angelopoulou2021,
author = {Angelopoulou, Foteini and Bogdanos, Dimitrios and Dimitroulas, Theodoros and Sakkas, Lazaros and Daoussis, Dimitrios},
title = {Immune checkpoint inhibitor-induced musculoskeletal manifestations},
journal = {Rheumatology International},
year = {2021},
volume = {41},
number = {1},
pages = {33--42},
doi = {10.1007/s00296-020-04665-7}
}
EUVIMED